{"name": "peginterferon beta-1a", "category": "drug", "content": "Peginterferon beta-1a, sold under the brand name Plegridy, is medication used to treat multiple sclerosis. The most common side effects include headache, muscle pain, joint pain, influenza (flu)-like symptoms, pyrexia (fever), chills, asthenia (weakness), and erythema (reddening of the skin), pain or pruritus (itching) at the injection site. Peginterferon beta-1a was approved for medical use in the United States and in the European Union in 2014.   == Medical uses == In the United States, peginterferon beta-1a is indicated for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. In the European Union, peginterferon beta-1a is indicated for the treatment of relapsing remitting multiple sclerosis in adults.   == References ==   == External links == Plegridy at the U.S. National Library of Medicine Medical Subject Headings (MeSH)"}